We previously reported that G-CSF, which is used for the prevention and therapy for neutropenia, enhanced the immunosuppressive activity of MDSCs through the glutathione degradation pathway, leading to tumor progression [14]; therefore, GM-CSF might also do so. This evidence concerns the gene CSF2 and neutropenia.